Cipla Partners With CSIR-CDRI To Develop Formulation For Fungal Keratitis
The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis, the Mumbai-based drug maker said in a statement.
Cipla Expects To Sustain 24% Ebitda Margin, Says Management
The company is looking to organically expand in India by increasing focus on chronic prescription.
CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("Listing Regulation"). CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Investor Presentation
In furtherance to our intimation dated 1st December 2023 with respect to our participation at the Nuvama India Conference 2024, the presentation to be discussed at the conference is enclosed and the same is also available on our website at www.cipla.com. CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on acquisition of Actor Pharma (Pty) Ltd., South Africa
Cipla Eyes Acquisitions, Inorganic Partnerships In U.S. Market
Cipla aims to expand in the U.S. through acquisitions and partnerships, while focusing on growth in Europe and margin expansion in South Africa. CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Further to our intimation dated 14th December, 2023, we hereby notify that closing conditions stated in definitive agreements signed by the Company on 14th December, 2023 have been met on 2nd February, 2024 and the Company has completed acquisition and subscription of additional shares in Goapptiv Private Limited, associate Company. Accordingly, Cipla will now hold 22.99% stake on a fully dilutive basis in Goapptiv. Cipla Q3 Results Review - Strong All-Round Performance: Nirmal Bang
We expect revenue/Ebitda/adjusted profit after tax to grow at 14%/19%/32% compound annual growth rate over FY23-FY25E. CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Buy Cipla; target of Rs 1660: ICICI Securities
ICICI Securities is bullish on Cipla recommended buy rating on the stock with a target price of Rs 1660 in its research report dated January 26, 2024.